Brostallicin

Drug Profile

Brostallicin

Alternative Names: PNU-166196; PNU-166196A; SMi-BX1

Latest Information Update: 31 Aug 2015

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Developer CTI BioPharma; National Cancer Institute (USA); Systems Medicine
  • Class Antineoplastics; DNA-binding proteins; Guanidines; Pyrroles; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Soft tissue sarcoma

Most Recent Events

  • 30 May 2014 Cell Therapeutics is now called CTI BioPharma
  • 01 Jun 2013 Final efficacy data from a Phase-II trial in Breast cancer (Metastatic disease, Combination therapy) presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
  • 05 Dec 2012 Interim efficacy and safety data from a phase II trial in Breast cancer presented at the 35th Annual San Antonio Breast Cancer Symposium (SABCS-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top